Development of a Poly (lactic-co-glycolic Acid) Particle Vaccine to Protect Against House Dust Mite Induced Allergy

Overview

Journal AAPS J

Specialty Pharmacology

Date 2014 Jul 2

PMID 24981892

Citations 26

Authors

Vijaya B Joshi

Andrea Adamcakova-Dodd

Xuefang Jing

Amaraporn Wongrakpanich

Katherine N Gibson-Corley

Peter S Thorne

Aliasger K Salem

Affiliations

Soon will be listed here.

Abstract

Poly(lactic-co-glycolic acid) (PLGA) particles carrying antigen and adjuvant is a promising vaccine system which has been shown to stimulate systemic antigen-specific immune responses. In this study, we investigated the relationship of (i) the sizes of PLGA particle and (ii) the presence of cytosine-phosphate-guanine motifs (CpG), with the extent and type of immune response stimulated against Dermatophagoides pteronyssinus-2 (Der p2) antigen. Different sizes of PLGA particles encapsulating CpG were prepared using a double emulsion solvent evaporation method. Mice were vaccinated with Der p2 and different sizes of empty or CpG-loaded PLGA particles. Vaccinated mice were exposed to daily intranasal instillation of Der p2 for 10 days followed by euthanization to estimate leukocyte accumulation in bronchoalveolar lavage (BAL) fluids, antibody profiles, and airway hyperresponsiveness. PLGA particles showed a size-dependent decrease in the proportion of eosinophils found in BAL fluids. Mice vaccinated with the Der p2 coated on 9-μm-sized empty PLGA particles showed increased levels of IgE and IgG1 antibodies as well as increased airway hyperresponsiveness. All sizes of PLGA particles encapsulating CpG prevented airway hyperresponsiveness after Der p2 exposures. Inflammatory responses to Der p2 exposure were significantly reduced when smaller PLGA particles were used for vaccination. In addition, encapsulating CpG in PLGA particles increased IgG2a secretion. This study shows that the size of PLGA particles used for vaccination plays a major role in the prevention of house dust mite-induced allergy and that incorporation of CpG into the PLGA particles preferentially develops a Th1-type immune response.

Citing Articles

Innovative approaches to asthma treatment: harnessing nanoparticle technology.

Goswami V, Sodhi K, Singh C Discov Nano. 2025; 20(1):21.

PMID: 39922940 PMC: 11807046. DOI: 10.1186/s11671-025-04211-z.

Application of Nanoparticles for Immunotherapy of Allergic Rhinitis.

Li K, Jin J, Yang Y, Luo X, Wang Y, Xu A Int J Nanomedicine. 2024; 19:12015-12037.

PMID: 39583318 PMC: 11584337. DOI: 10.2147/IJN.S484327.

Potential of DPD ((S)-4,5-dihydroxy-2,3-pentanedione) Analogs in Microparticulate Formulation as Vaccine Adjuvants.

Joshi D, Shah S, Chbib C, Uddin M Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399399 PMC: 10891675. DOI: 10.3390/ph17020184.

A novel peanut allergy immunotherapy: Plant-based enveloped Ara h 2 Bioparticles activate dendritic cells and polarize T cell responses to Th1.

Castenmiller C, Nagy N, Kroon P, Auger L, Desgagnes R, Martel C World Allergy Organ J. 2023; 16(11):100839.

PMID: 38020282 PMC: 10679945. DOI: 10.1016/j.waojou.2023.100839.

Immunomodulatory Effects of Subacute Inhalation Exposure to Copper Oxide Nanoparticles in House Dust Mite-Induced Asthma.

Areecheewakul S, Adamcakova-Dodd A, Zacharias Z, Jing X, Meyerholz D, Legge K ACS Nano. 2023; 17(15):14586-14603.

PMID: 37463491 PMC: 10416562. DOI: 10.1021/acsnano.3c01668.

References

Burks A, Calderon M, Casale T, Cox L, Demoly P, Jutel M . Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013; 131(5):1288-96.e3. DOI: 10.1016/j.jaci.2013.01.049. View

Arlian L, Morgan M, Neal J . Dust mite allergens: ecology and distribution. Curr Allergy Asthma Rep. 2002; 2(5):401-11. DOI: 10.1007/s11882-002-0074-2. View

Zhang F, Huang G, Hu B, Song Y, Shi Y . Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination. Clin Vaccine Immunol. 2011; 18(5):807-14. PMC: 3122522. DOI: 10.1128/CVI.00434-10. View

Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde R, Madan R . Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature. 2008; 457(7229):585-8. PMC: 2843411. DOI: 10.1038/nature07548. View

Joshi V, Geary S, Salem A . Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2012; 15(1):85-94. PMC: 3535111. DOI: 10.1208/s12248-012-9418-6. View

Bosnjak B, Stelzmueller B, Erb K, Epstein M . Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res. 2011; 12:114. PMC: 3179723. DOI: 10.1186/1465-9921-12-114. View

Standley S, Mende I, Goh S, Kwon Y, Beaudette T, Engleman E . Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Bioconjug Chem. 2007; 18(1):77-83. DOI: 10.1021/bc060165i. View

Van Ree R, Antonicelli L, Akkerdaas J, Garritani M, Aalberse R, Bonifazi F . Possible induction of food allergy during mite immunotherapy. Allergy. 1996; 51(2):108-13. View

Bharadwaj A, Bewtra A, Agrawal D . Dendritic cells in allergic airway inflammation. Can J Physiol Pharmacol. 2007; 85(7):686-99. DOI: 10.1139/Y07-062. View

10.

Gregory L, Lloyd C . Orchestrating house dust mite-associated allergy in the lung. Trends Immunol. 2011; 32(9):402-11. PMC: 3381841. DOI: 10.1016/j.it.2011.06.006. View

11.

Scholl I, Kopp T, Bohle B, Jensen-Jarolim E . Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy. Immunol Allergy Clin North Am. 2006; 26(2):349-64, ix. DOI: 10.1016/j.iac.2006.02.007. View

12.

Fonseca D, Kline J . Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009; 61(3):256-62. DOI: 10.1016/j.addr.2008.12.007. View

13.

Kidon M, Chiang W, Chin C, Liew W, Kang L, Ong T . Mite component-specific IgE repertoire and phenotypes of allergic disease in childhood: the tropical perspective. Pediatr Allergy Immunol. 2011; 22(2):202-10. DOI: 10.1111/j.1399-3038.2010.01094.x. View

14.

Huang T, Macary P, Eynott P, Moussavi A, Daniel K, Askenase P . Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma. J Immunol. 2000; 166(1):207-17. DOI: 10.4049/jimmunol.166.1.207. View

15.

Eifan A, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler N . Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010; 40(6):922-32. DOI: 10.1111/j.1365-2222.2009.03448.x. View

16.

Suzuki K, Kaminuma O, Yang L, Takai T, Mori A, Umezu-Goto M . Prevention of allergic asthma by vaccination with transgenic rice seed expressing mite allergen: induction of allergen-specific oral tolerance without bystander suppression. Plant Biotechnol J. 2011; 9(9):982-90. DOI: 10.1111/j.1467-7652.2011.00613.x. View

17.

Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S . Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett. 2013; 151(1-2):23-30. DOI: 10.1016/j.imlet.2013.01.013. View

18.

Arbes Jr S, Cohn R, Yin M, Muilenberg M, Burge H, Friedman W . House dust mite allergen in US beds: results from the First National Survey of Lead and Allergens in Housing. J Allergy Clin Immunol. 2003; 111(2):408-14. DOI: 10.1067/mai.2003.16. View

19.

Kline J, Krieg A . Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008; 21(8):434-9. DOI: 10.1358/dnp.2008.21.8.1272133. View

20.

Akinbami L, Moorman J, Bailey C, Zahran H, King M, Johnson C . Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief. 2012; (94):1-8. View